Quick Takeaways
- BLTE - BELITE BIO, INC financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Current Ratio 50.02x.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2025-12-31) highlights Current Ratio 50.02x.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
4.0/100
Weak Confidence low
No strong signals yet.
Current Ratio
Current Ratio
50.02x
YoY: +106%
Industry median: 3.39x (n=667)
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 50.02x | +106% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 39,339,960 | +24% |
| Common Stock, Shares, Outstanding | 39,339,960 | +24% |
| Common Stock, Value, Issued | $4,000 | +33% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.